SLC5A2 and angina pectoris: By optimizing cardiac hemodynamics and improving myocardial metabolism, SGLT2 inhibitors may enhance cardiac efficiency, reducing the frequency of ischemic episodes and angina in vulnerable post-AMI populations (Yu et al., 2021).